Metformin is the first-line drug that can lower blood sugar levels in type 2 diabetes patients. One third of patients do not respond to metformin treatment and 5 per cent experience serious side effects, which is the reason many choose to stop medicating. Researchers at Lund University in Sweden have now identified biomarkers that can show in advance how the patient will respond to metformin treatment via a simple blood test.
The University of Alabama at Birmingham and Southern Research have discovered a new drug candidate that offers a major advance in the treatment for diabetes.
It is estimated that 7.3% of the global adult population has some alterations in their metabolism resulting in hyperglycemia, an increase in blood sugar, not to the range we determine is diabetes, but heading in that direction, the individual with “prediabetes.”
Intermittent fasting is known to improve sensitivity to the blood glucose-lowering hormone insulin and to protect against fatty liver. DZD scientists from DIfE have now discovered that mice on an intermittent fasting regimen also exhibited lower pancreatic fat. In their current study published in the journal Metabolism, the researchers showed the mechanism by which pancreatic fat could contribute to the development of type 2 diabetes.
‘The science told us this should work, and so we kept at it,’ says key scientist after 33-year research journey